Efficacy And Safety Of Bradykinin B2 Receptor Antagonism With Oral Deucrictibant In Prophylaxis Of Hereditary Angioedema Attacks: Results Of CHAPTER-1 Phase 2 Trial

In hereditary angioedema (HAE), swelling attacks are caused by excessive bradykinin activating the bradykinin B2 receptors. Deucrictibant (PHA121) is a potent, selective, orally administered antagonist of bradykinin B2 receptor under development for on-demand and prophylactic treatment of HAE attacks.

Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Marc Riedl, John Anderson, Francesco Arcoleo, Mauro Cancian, Hugo Chapdelaine, Niall Conlon, Efrem Eren, Mark Gompels, Sofia Grigoriadou, Maria Guarino, Padmalal Gurugama, Tamar Kinaciyan, Markus Magerl, Michael Manning, Marcin Stobiecki, Michael Tarzi, A Source Type: research